This is a routine scientific conference preview with no material new data. The actual data presentations at EHA2026 (June 11-14) could move the stock if they show meaningful efficacy or safety signals. Monitor the abstract releases and presentation dates for potential catalysts.
Price Chart
Executive Summary
Ascentage Pharma announced it will present 17 clinical advances, including 8 poster presentations, at the upcoming EHA2026 Congress (June 11-14). The abstracts cover its two approved products, Olverembatinib and Lisaftoclax, across multiple ongoing studies. This is a routine scientific conference update with no new clinical data or financial disclosures — the filing itself is a standard 6-K furnishing a press release.
Key Facts
- 17 clinical advances will be featured at the 31st Congress of the European Hematology Association (EHA2026) in Stockholm, June 11-14, 2026.
- 8 poster presentations are included, covering Olverembatinib and Lisaftoclax across multiple indications.
- Key abstracts include updated POLARIS-1 Phase 3 data for Olverembatinib in Ph+ ALL and a Phase 1b study of Olverembatinib + Lisaftoclax in pediatric R/R Ph+ ALL.
- No new efficacy or safety data were released in this filing — only abstract titles and presentation logistics.
- Olverembatinib and Lisaftoclax remain investigational in the U.S. and have not received FDA approval.
Financial Impact
No financial figures disclosed in this filing.
Risk Factors
- No new clinical data were released — the market may view this as a non-event.
- Both lead assets remain unapproved by the FDA, limiting near-term U.S. commercial upside.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-055466 |
| Document: ea0290504-6k_ascentage.htm | 0001213900-26-055466 |
| Document: 0001213900-26-055466-index-headers.html | 0001213900-26-055466 |
| Document: 0001213900-26-055466-index.html | 0001213900-26-055466 |
| Document: 0001213900-26-055466.txt | 0001213900-26-055466 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $15.44 $15.45 | ▲ +0.06% | ▼ −0.65% | $14.77 (−4.34%) |
Oct 21, 2026 5d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $14.77 (−1.01%) |
Oct 15, 2026 12d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $14.77 (+0.54%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $14.77 (+3.90%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $14.77 (+14.72%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $14.77 (−12.37%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $14.77 (−12.11%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $14.77 (−21.81%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $14.77 (−19.60%) |
Jul 13, 2026 15w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $14.77 (−23.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers